Aurobindo buys parts of Sandoz US from Novartis for â¹6,480 cr
India's second-largest drugmaker Aurobindo Pharma has agreed to buy dermatology and oral solids businesses of Sandoz US, a division of Switzerland's Novartis, for $900 million (â¹6,480 crore). The purchase, which will be the largest outbound pharma deal by an Indian firm, also comprises commercial and manufacturing infrastructure in the US. The acquired business had sales of $1.2 billion in 2017.